Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBT-002
- Development stage
- Preclinical
- Lead developer
- Ernest Pharmaceuticals
- Modality
- Drug Delivery Systems
- Administration
- Intravenous
01
Overview
EBT-002 is a preclinical biological therapeutic developed by Ernest Pharmaceuticals for the treatment of advanced solid tumors, such as liver cancer. It utilizes the company's proprietary Bacterial Intracellular Delivery (BacID) vector platform. This bacterial therapy is designed to specifically target tumor cells and deliver a biological payload that activates caspase-3, an key enzyme in the apoptotic (cell death) pathway. The intended mechanism is to induce apoptosis in cancer cells while minimizing damage to healthy tissues. The drug is currently in the IND-enabling phase of development.
Beyond the preview
Go deeper on EBT-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBT-002.